ArticleJugan geon-gang gwa jilbyeong2023
[Long-Term Prognosis of Chronic Kidney Disease Patients in the Republic of Korea: From the KNOW-CKD Study].
Article in Jugan geon-gang gwa jilbyeong, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to investigate the incidences of renal events, all-cause deaths, and cardiovascular events from Korean chronic kidney disease (CKD) patients. This study was conducted using the data obtained from the 'KoreaN cohort study for Outcome in patients With CKD (KNOW-CKD),' a long-term prospective cohort study of CKD in the Republic of Korea (ROK). From January 2011 to June 2016, adult non-dialyzed CKD patients aged 20-75 were enrolled at nine hospitals in the ROK. During follow-up until March 31, 2022, the glomerular filtration rate declined at a rate of 2.62±0.07 ml/min/1.73 m2/year on the average. During the follow-up, 183 deaths (11.7 per 1,000 person-years), 221 cardiovascular events (15.2 per 1,000 person-years), and 689 dialysis or transplantation events (53.1 per 1,000 person-years) occurred. All-cause mortality and incidence of cardiovascular disease (CVD) were the highest in the diabetic nephropathy group, and tended to increase at higher CKD stages. Compared to the general population, CKD patients exhibited higher risk of adverse outcomes; the hazard ratio (HR) for all-cause mortality was 2.25 (95% confidence interval [CI] 1.95-2.60), and the HR for cardiovascular events was 1.42 (95% CI 1.00-2.02). All-cause mortality risk In CKD patients in all CKD stages significantly increased compared to that in the general population. In a meta-analysis and international comparison study, Korean CKD patients exhibited relatively higher risk of renal events, while they demonstrated relatively lower all-cause mortality and CVD risk. These results provide an important implication in establishing national policies and treatment plan for Korean CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.